胰高血糖素样肽-1的心血管益处及机制  

Cardiovascular benefits of glucagon-like peptide-1 and the mechanisms

作　　者：钟兴[1] 刘媛媛[1] 肖海鹏[1] 

机构地区：[1]中山大学附属第一医院内分泌科,广州510080

出　　处：《中国新药杂志》2011年第21期2080-2085,共6页Chinese Journal of New Drugs

摘　　要：心血管疾病是2型糖尿病患者的主要死亡原因之一。新近研究发现胰高血糖素样肽-1(GLP-1)不仅通过葡萄糖依赖的方式刺激胰岛素分泌和抑制糖原的不适当分泌,延缓胃排空,增加饱食感等方式调节血糖;还能通过GLP-1R和受体以外的方式发挥心血管保护作用,包括心肌、内皮细胞和血管等。越来越多的动物和临床研究显示,GLP-1和GLP-1R激动剂都能改善内皮细胞功能、促进钠的排泄、改善缺血损伤的心肌和心功能的恢复,减少心血管风险的危险因素和标志物。文中综述有关动物和人类研究中GLP-1对心血管系统的作用以及可能机制。Cardiovascular disease （CVD） is one of the leading causes of death in patients with type 2 diabetes. Recent studies have shown that glucagon-like peptide-1 （ GLP-1 ） regulates blood glucose concentrations; the mechanisms include enhancing insulin secretion, suppressing glucagon secretion, slowing gastric emptying, and enhancing satiety. GLP-1 also exerts a beneficial effect on myocardium, endothelium and vasculature mediated by the GLP-1 receptors （GLP-1R） and the GLP-1R-independent pathways. Growing lines of evidence from animal and clinical studies suggests that GLP-1 favorably affects endothelial function, sodium excretion, recovery from ischemic injury and myocardial function, and reduces the markers of CVD. In this review, we summarized the cardiovascular effect of GLP-1 and the mechanisms based on both animal and human studies.

关 键 词：胰高血糖素样肽-1 2型糖尿病 心血管疾病 利拉鲁肽 艾塞那肽 

分 类 号：R977.15[医药卫生—药品]